Page last updated: 2024-09-05
ly 97241 and l 365260
ly 97241 has been researched along with l 365260 in 1 studies
Compound Research Comparison
Studies (ly 97241) | Trials (ly 97241) | Recent Studies (post-2010) (ly 97241) | Studies (l 365260) | Trials (l 365260) | Recent Studies (post-2010) (l 365260) |
---|---|---|---|---|---|
11 | 0 | 1 | 422 | 10 | 8 |
Protein Interaction Comparison
Protein | Taxonomy | ly 97241 (IC50) | l 365260 (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0081 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0081 | |
Cholecystokinin receptor type A | Rattus norvegicus (Norway rat) | 0.4981 | |
Gastrin/cholecystokinin type B receptor | Rattus norvegicus (Norway rat) | 0.039 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0081 | |
Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | 5 | |
Cholecystokinin receptor type A | Homo sapiens (human) | 0.1585 | |
Gastrin/cholecystokinin type B receptor | Homo sapiens (human) | 0.0079 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 5 | |
Cholecystokinin receptor type A | Cavia porcellus (domestic guinea pig) | 0.044 | |
Cysteinyl leukotriene receptor 2 | Homo sapiens (human) | 5 | |
Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | 5 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
Other Studies
1 other study(ies) available for ly 97241 and l 365260
Article | Year |
---|---|
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |